MedinCell SA (MEDCL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a €25.00 price target.
Ram Selvaraju has given his Buy rating due to a combination of factors related to MedinCell SA’s promising developments and strategic collaborations. The initiation of a long-acting injectable formulation of macozinone, in partnership with iM4TB, is a significant step forward in addressing tuberculosis treatment challenges. This collaboration, part of the ERA4TB program, aims to improve patient adherence and reduce drug resistance, which are critical in combating this deadly disease.
Additionally, MedinCell’s partnership with Teva Pharmaceutical Industries for the UZEDY extended-release injectable suspension presents a substantial growth opportunity. The submission of a supplemental New Drug Application for UZEDY’s use in treating bipolar disorder I could expand the market and enhance revenue through royalties. Furthermore, the successful completion of the pivotal Phase 3 trial for the olanzapine long-acting injectable in schizophrenia, with positive efficacy results, strengthens MedinCell’s position in the market. These strategic advancements underpin Selvaraju’s confidence in MedinCell’s future prospects, justifying the Buy rating.
According to TipRanks, Selvaraju is a 2-star analyst with an average return of 0.0% and a 34.61% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Axsome Therapeutics, and Anavex Life Sciences.